Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine Inc (NASDAQ: EDIT), a leader in CRISPR-based genome editing, provides this centralized hub for tracking all corporate developments and scientific advancements. Access real-time updates on clinical trial progress, regulatory milestones, and financial disclosures essential for monitoring this pioneering biotech firm.
This resource aggregates EDIT's press releases, partnership announcements, and peer-reviewed research findings. Investors will find critical updates on pipeline therapies for genetic disorders, while analysts gain insights into strategic initiatives shaping the genomic medicine landscape. Content spans quarterly earnings, intellectual property developments, and preclinical breakthroughs.
Key categories include therapy authorization updates, collaboration agreements with research institutions, and presentations at major medical conferences. All materials are sourced directly from Editas Medicine and verified financial filings to ensure reliability.
Bookmark this page for efficient tracking of EDIT's progress in developing CRISPR/Cas9 and Cas12a therapies. Check regularly for authoritative updates on one of biotech's most innovative gene-editing platforms.
Editas Medicine has regained full global rights to develop and commercialize ocular medicines, including EDIT-101 for Leber congenital amaurosis 10, after terminating a previous alliance with Allergan, now part of AbbVie. CEO Cynthia Collins expressed optimism about advancing EDIT-101, with dosing resuming in the Phase 1/2 BRILLIANCE trial. They aim to complete dosing of the adult low-dose cohort and dose adult mid-dose patients by year-end. J.P. Morgan Securities LLC is advising Editas on this transition.
Editas Medicine (Nasdaq: EDIT) has partnered with Catalent to enhance the development and manufacturing of its in vivo CRISPR medicines and engineered cell therapies. Catalent will support Editas with clinical supply and production from its facilities in Maryland and Texas, ensuring efficient delivery to clinical trial sites. This collaboration aims to leverage Catalent's advanced technologies to expedite Editas' innovative therapies, potentially improving patient access to new treatments.
Editas Medicine has appointed Gad Berdugo as the new Chief Business Officer, effective immediately. Berdugo brings over 25 years of experience in biotech corporate development and business strategy. He previously held executive roles at EpiVax Oncology and Immune Pharmaceuticals. Under his leadership, Editas aims to enhance its business development and advance its clinical and preclinical pipeline, which includes ongoing trials and strategic partnerships. President Cynthia Collins expressed confidence in Berdugo's ability to drive the company’s growth amidst the dynamic gene editing landscape.
Editas Medicine, a leader in genome editing, will host a conference call on August 6, 2020, at 5:00 p.m. ET to discuss its corporate updates and Q2 2020 results. Participants can join the call by dialing 844-348-3801 (domestic) or 213-358-0955 (international) and using passcode 9185596. A live webcast will also be available on their website. Editas focuses on leveraging CRISPR technology to develop transformative genomic treatments for serious diseases worldwide.
On June 26, 2020, Editas Medicine (Nasdaq: EDIT) announced the completion of its underwritten public offering, selling 6,900,000 shares of common stock at a price of $31.25 per share. The offering generated approximately $215.6 million in gross proceeds, which includes 900,000 shares sold due to underwriter options. The registration statement related to the offering has been filed and is effective with the SEC. Morgan Stanley acted as the sole book-running manager for this offering.
Editas Medicine has announced an underwritten offering of 6,000,000 shares of its common stock at a price of $31.25 per share, aiming for gross proceeds of approximately $187.5 million. The offering features a 30-day option for underwriters to purchase an additional 900,000 shares. Scheduled to close around June 26, 2020, this transaction is being managed by Morgan Stanley and follows a Form S-3 registration with the SEC.
Editas Medicine (Nasdaq: EDIT) announced plans to offer 4,000,000 shares of common stock in a public offering, with the potential to sell an additional 600,000 shares. The offering will be managed by Morgan Stanley and is subject to market conditions. A registration statement has been filed with the SEC, and the offering details will be available through the final prospectus. Editas aims to utilize the funds to advance its CRISPR-based therapeutic pipeline targeting serious diseases. The offering carries uncertainties regarding completion and final terms.
Editas Medicine (Nasdaq: EDIT) announced promising results from a pre-clinical study of EDIT-301, a gene therapy aimed at treating sickle cell disease. The study showcased a high editing efficiency of approximately 90% in both in vitro and in vivo settings. Additionally, red blood cells derived from EDIT-301 demonstrated over 50% fetal hemoglobin (HbF) expression and significant improvements in cell deformability, indicating potential clinical benefits. The company aims to file an IND for EDIT-301 by the year's end, marking a pivotal step in its development.
Editas Medicine (Nasdaq: EDIT) announced results from a pre-clinical study showcasing the efficacy of its engineered CRISPR-Cas12a technology in iPSC-derived natural killer (iNK) cells for treating solid tumor cancers. The study, presented virtually at the 23rd ASGCT Annual Meeting, demonstrated that edited iNK cells exhibited enhanced tumor-killing activity compared to unedited counterparts. Editas is advancing its oncology programs, including IND-enabling studies for its HDNK engineered cell medicine and collaborations for T cell therapies.
FAQ
What is the current stock price of Editas Medicine (EDIT)?
What is the market cap of Editas Medicine (EDIT)?
